Breo ellipta and Tobramycin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Breo ellipta (fluticasone furoate; vilanterol trifenatate) and Tobramycin (tobramycin). Common drug interactions include nausea among females and secretion discharge among males.

The phase IV clinical study analyzes what interactions people have when they take Breo ellipta and Tobramycin. It is created by eHealthMe based on reports of 26 people who take the same drugs from the FDA, and is updated regularly.

What is Breo ellipta?

Breo ellipta has active ingredients of fluticasone furoate; vilanterol trifenatate. It is often used in asthma. eHealthMe is studying from 37,362 Breo ellipta users. Check the latest studies of Breo ellipta.

What is Tobramycin?

Tobramycin has active ingredients of tobramycin. It is often used in cystic fibrosis. eHealthMe is studying from 3,579 Tobramycin users. Check the latest studies of Tobramycin.

On Jul, 17, 2026

26 people who take Breo ellipta and Tobramycin together, and have interactions are studied.

Breo ellipta and Tobramycin drug interactions.

What are the common drug interactions of Breo Ellipta and Tobramycin, by gender? *:

female:

Nausea (feeling of having an urge to vomit)
Nephrogenic anaemia (anaemia due to kidney disease)
Onychoclasis (breaking of the nails)
Osteonecrosis (death of bone)
Osteopenia (a condition where bone mineral density is lower than normal)
Peripheral swelling
Pneumonia fungal
Procedural pain
Proteinuria (presence of protein in the urine)
Renal failure (kidney dysfunction)

male:

Secretion discharge
Arthralgia (joint pain)
Asbestosis (chronic lung disease caused by scarring of lung tissue, which stems from prolonged exposure to asbestos)
Asthenia (weakness)
Blood pressure systolic increased
Bronchial disorder
Bronchiolitis (inflammation of the membranes lining the bronchioles in lungs)
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Catheter site bruise
Cellulitis (infection under the skin)

What are the common drug interactions of Breo Ellipta and Tobramycin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Abdominal pain
Drug hypersensitivity
Eye irritation
Injection site bruising
Injection site pain
Injection site swelling
Peripheral swelling

30-39:

Arthralgia (joint pain)
Decreased appetite
Fatigue (feeling of tiredness)
Insomnia (sleeplessness)
Nausea (feeling of having an urge to vomit)
Procedural pain

40-49:

n/a

50-59:

Chronic kidney disease
Bone density decreased
Ear infection
Fall
Haemorrhage (bleeding)
Multiple fractures
Osteopenia (a condition where bone mineral density is lower than normal)
Osteoporosis (bones weak and more likely to break)
Pneumonia
Sinusitis (inflammation of sinus)

60+:

Pneumonia
Contusion (a type of hematoma of tissue in which capillaries)
Sinusitis (inflammation of sinus)
Vasculitis (inflammation of a blood vessel or blood vessels)
Fall
Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
Joint dislocation (a joint position is changed from normal position)
Ligament sprain (ligament stretched)
Asbestosis (chronic lung disease caused by scarring of lung tissue, which stems from prolonged exposure to asbestos)
Asthenia (weakness)

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 4 people, 15.38%
Hiv Infection: 4 people, 15.38%
Sinusitis (inflammation of sinus): 2 people, 7.69%
Sinus Disorder (disease of sinus): 2 people, 7.69%
Primary Immunodeficiency Syndrome: 2 people, 7.69%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 7.69%
Cystic Fibrosis Lung (fibrosis with cyst in the lung): 2 people, 7.69%
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection): 2 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Breo ellipta and Tobramycin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously